173 related articles for article (PubMed ID: 28122348)
21. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
22. Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.
Bapat SA; Krishnan A; Ghanate AD; Kusumbe AP; Kalra RS
Cancer Res; 2010 Jun; 70(12):4809-19. PubMed ID: 20530682
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
24. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
25. NFATc1 regulates cell proliferation, migration, and invasion of ovarian cancer SKOV3 cells in vitro and in vivo.
Li L; Duan Z; Yu J; Dang HX
Oncol Rep; 2016 Aug; 36(2):918-28. PubMed ID: 27350254
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
27. AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.
Ardizzoia A; Jemma A; Redaelli S; Silva M; Bentivegna A; Lavitrano M; Conconi D
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511212
[TBL] [Abstract][Full Text] [Related]
28. Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression.
Du Y; Wu J; Zhang H; Li S; Sun H
Mol Med Rep; 2017 Apr; 15(4):1638-1646. PubMed ID: 28259910
[TBL] [Abstract][Full Text] [Related]
29. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.
McIntyre JB; Rambau PF; Chan A; Yap S; Morris D; Nelson GS; Köbel M
Histopathology; 2017 Feb; 70(3):347-358. PubMed ID: 27575406
[TBL] [Abstract][Full Text] [Related]
31. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
33. Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.
Li J; Chen Z; Xiao W; Liang H; Liu Y; Hao W; Zhang Y; Wei F
J Cell Mol Med; 2023 Nov; 27(21):3259-3270. PubMed ID: 37525498
[TBL] [Abstract][Full Text] [Related]
34. Hiding in the dark: uncovering cancer drivers through image-guided genomics.
Yoshihara K; Verhaak RG
Genome Biol; 2014 Dec; 15(12):563. PubMed ID: 25608759
[TBL] [Abstract][Full Text] [Related]
35. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
[TBL] [Abstract][Full Text] [Related]
36. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor gene mutations do not occur in ovarian cancer.
Engehausen DG; Tong XW; Oehler MK; Freund CT; Schrott KM; Kieback DG
Anticancer Res; 2000; 20(2A):815-9. PubMed ID: 10810359
[TBL] [Abstract][Full Text] [Related]
38. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro.
Takei Y; Mizukami H; Saga Y; Kobayashi H; Suzuki M; Matsushita T; Ozawa K; Suzuki M
Int J Cancer; 2005 Jan; 113(1):54-8. PubMed ID: 15386422
[TBL] [Abstract][Full Text] [Related]
40. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.
Cope L; Wu RC; Shih IeM; Wang TL
Gynecol Oncol; 2013 Mar; 128(3):500-5. PubMed ID: 23200914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
